NCT05721950 2026-02-18
Brilliant
Takeda
Active not recruiting
Clinical Trials
5 trialsNCT05834348 2025-03-30
DELINOR
Pfizer
Completed
NCT06532149 2024-08-09
EROS
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT03546894 2024-07-15
A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors
Takeda
Completed
NCT04647110 2023-04-06
Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.
Pfizer
Completed